Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM)

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis

(2018) F Poggio et al.   ANNALS OF ONCOLOGY

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

(2018) Sibylle Loibl et al.   LANCET ONCOLOGY

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

(2018) Andrew Tutt et al.   NATURE MEDICINE

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

(2018) Claudia Omarini et al.   Cancer Management and Research

Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy

(2018) Elaine M. Walsh et al.   BREAST CANCER RESEARCH AND TREATMENT

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

(2017) Norikazu Masuda et al.   NEW ENGLAND JOURNAL OF MEDICINE

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

(2017) Eric Hahnen et al.   JAMA Oncology

Targeted sequencing ofBRCA1andBRCA2across a large unselected breast cancer cohort suggests that one-third of mutations are somatic

(2016) C. Winter et al.   ANNALS OF ONCOLOGY

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines

(2016) Pablo Alonso-Coello et al.   BMJ-British Medical Journal

The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines

(2016) Melissa C Brouwers et al.   BMJ-British Medical Journal

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines

(2016) Pablo Alonso-Coello et al.   BMJ-British Medical Journal

The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines

(2016) Melissa C Brouwers et al.   BMJ-British Medical Journal

Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates

(2015) Mehra Golshan et al.   ANNALS OF SURGERY

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers

(2015) Mohammed Aleskandarany et al.   BREAST CANCER RESEARCH AND TREATMENT

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future

(2015) A. Avan et al.   ONCOLOGIST

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression

(2014) Masashi Ando et al.   BREAST CANCER RESEARCH AND TREATMENT

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

(2012) E. Alba et al.   BREAST CANCER RESEARCH AND TREATMENT

CMF revisited in the 21st century

(2011) E. Munzone et al.   ANNALS OF ONCOLOGY

Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?

(2010) N. Berrada et al.   ANNALS OF ONCOLOGY

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

(2009) Tomasz Byrski et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY